All News

RheumNow Podcast square

Happy Diwali (11.1.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Knee,pain,OA,DJD

GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain

MedPage Today

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 Inhibitor Protective Effects in Lupus

Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
RA.Ow02.jpg

Filgotinib Efficacy and Safety - 3 Years Later

MedPage Today

Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.

Read Article
switch.jpg

Swapping is Better than Cycling in Psoriatic Arthritis

Jack Cush, MD

A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.

Read Article
dupuytrens

Treatment Options for Dupuytren’s Contracture

Jack Cush, MD

The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.

Read Article
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
106-0674_IMG.JPG

Potential OA Treatment - Chemokine CCL17 Inhibition

MedPage Today

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.

Read Article
juvDM1.jpg

Long-term Tofacitinib in Juvenile Idiopathic Arthritis

Jack Cush, MD

The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.

Read Article
pregn.outcome.jpg

Predictors of Adverse Pregnancy Outcomes in Lupus

Jack Cush, MD

A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at concept

Read Article
deperssion.woman

Anxiety and Depression Rising in Rheumatoid Arthritis

Jack Cush, MD

A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).

Read Article
SGLT2 Inhibitor Protective Effects in Lupus Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D). https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN

Links:

Dr. John Cush RheumNow ( View Tweet)
Swapping is Better than Cycling in Psoriatic Arthritis A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush RheumNow ( View Tweet)
Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN) - 60% PGN w ≤1 g/d proteinuria (more renal recovery) - 79% w/ 1-3g/d - 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush RheumNow ( View Tweet)
Real-world study of 76 #PsA pts (Dz Duration Psoriasis 216 mos, PsA 120 mos. No correlatons seen between skin/PASI scores and PsA clinical variables, except the signif correlation betw PASI & enthesitis (ρ = 0.285; p = 0.013). https://t.co/K6FXjE5A4N https://t.co/NVlPiPVT0s

Links:

Dr. John Cush RheumNow ( View Tweet)
Pain Relief in RA: JAK Better than TNF Inhibitors? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of Adverse Pregnancy Outcomes in Lupus A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before… https://t.co/31dqOyD3ZR https://t.co/L9LMn2CPYS
Dr. John Cush RheumNow ( View Tweet)
Biomarker substudy of #SLE Rx w/ low dose IL-2 Rx in 342 pts (40% responders). SRI-4 predicted by rash, proteinuria, uRBC, %CD4 T cells, C3 (AUC 0.9330; however renal markers did not correlate with achieving LLDAS. https://t.co/pDgwegbU6t https://t.co/72w4gNAiWt

Links:

Dr. John Cush RheumNow ( View Tweet)
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective population study of 383 #AS women who were pregnant (3.8/100,000) compared to controls. AS-Preg pts more likely to be older; White, w/ higher incomes, MORE thyroid Dz, Pregs, C-Sections, gestational DM, placenta previa, more neonatal SGA, IUFD… https://t.co/pgsmKgljwx https://t.co/IMJ8CTrqhY
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×